A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

This study is testing whether adding a new drug called mosliciguat to an existing inhaled medication (treprostinil) improves outcomes for people with pulmonary hypertension caused by interstitial lung disease (PH-ILD) — a condition where high blood pressure in the lungs is caused by scarring of the lung tissue. **You may be eligible if...** - You have been diagnosed with interstitial lung disease (ILD), such as idiopathic interstitial pneumonia, chronic hypersensitivity pneumonitis, or ILD related to connective tissue disease - You already use inhaled treprostinil - You have confirmed high blood pressure in your lungs (pulmonary hypertension), verified by a right heart catheterization - You are able to walk at least 100 meters in a 6-minute walk test **You may NOT be eligible if...** - Your pulmonary hypertension is caused by something other than lung disease (e.g., left-heart problems or blood clots) - You have had a flare of your lung disease in the last 28 days - You require very high levels of supplemental oxygen (more than 10 L/min at rest) - You have previously tried mosliciguat and did not tolerate it Talk to your doctor to see if this trial is right for you.